UY38153A - Formulaciones acuosas estables de anticuerpos anti-tau - Google Patents

Formulaciones acuosas estables de anticuerpos anti-tau

Info

Publication number
UY38153A
UY38153A UY38153A UY38153A UY38153A UY 38153 A UY38153 A UY 38153A UY 38153 A UY38153 A UY 38153A UY 38153 A UY38153 A UY 38153A UY 38153 A UY38153 A UY 38153A
Authority
UY
Uruguay
Prior art keywords
stable aqueous
aqueous formulations
tau antibodies
stable
abbv
Prior art date
Application number
UY38153A
Other languages
English (en)
Inventor
Martin Huelsmeyer
Jonas Angstenberger
Tanja Meyer
Axel Wilbertz
Kathrin Schaeker-Theobald
Katharina Kaleta
Kerstin Appenzeller
Christine Rinn
Christian Ried
Michael Siedler
Original Assignee
Abbvie Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Deutschland filed Critical Abbvie Deutschland
Publication of UY38153A publication Critical patent/UY38153A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Composiciones acuosas estables de pH amortiguado, que comprenden una alta concentración de ABBV-8E12, por ejemplo una composición acuosa estable de pH amortiguado que incluye ABBV-8E12 en una concentración de aproximadamente 100 mg/ml, por lo menos un amortiguador de pH, un excipiente, un tensioactivo, y opcionalmente un antioxidante.
UY38153A 2018-03-23 2019-03-25 Formulaciones acuosas estables de anticuerpos anti-tau UY38153A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862647615P 2018-03-23 2018-03-23

Publications (1)

Publication Number Publication Date
UY38153A true UY38153A (es) 2019-10-31

Family

ID=65991783

Family Applications (1)

Application Number Title Priority Date Filing Date
UY38153A UY38153A (es) 2018-03-23 2019-03-25 Formulaciones acuosas estables de anticuerpos anti-tau

Country Status (12)

Country Link
US (1) US20210023216A1 (es)
EP (1) EP3768706A1 (es)
JP (1) JP2021519268A (es)
CN (1) CN112004827A (es)
AR (1) AR117407A1 (es)
AU (1) AU2019237252A1 (es)
BR (1) BR112020019065A2 (es)
CA (1) CA3094934A1 (es)
MX (1) MX2020009935A (es)
TW (1) TW202003036A (es)
UY (1) UY38153A (es)
WO (1) WO2019180261A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2970453B1 (en) 2013-03-13 2019-12-04 Prothena Biosciences Limited Tau immunotherapy
WO2017191559A1 (en) 2016-05-02 2017-11-09 Prothena Biosciences Limited Tau immunotherapy
CU24537B1 (es) 2016-05-02 2021-07-02 Prothena Biosciences Ltd Anticuerpos monoclonales que compiten por unirse a tau humano con el anticuerpo 3d6
IL270375B1 (en) 2017-05-02 2024-08-01 Prothena Biosciences Ltd Antibodies that recognize tau
CU20210073A7 (es) 2019-03-03 2022-04-07 Prothena Biosciences Ltd Anticuerpos que se unen dentro de la región de unión a microtúbulos de tau definida por cdrs

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201401995UA (en) * 2009-05-04 2014-08-28 Abbvie Biotechnology Ltd Stable high protein concentration formulations of human anti-tnf-alpha-antibodies
SG11201408626YA (en) 2012-07-03 2015-03-30 Univ Washington Antibodies to tau
TWI734975B (zh) 2014-06-27 2021-08-01 美商Ｃ２Ｎ醫療診斷有限責任公司 人類化抗-tau抗體
TWI705827B (zh) * 2014-11-07 2020-10-01 瑞士商諾華公司 治療眼部疾病之方法
US20200030445A1 (en) * 2015-06-12 2020-01-30 C2N Diagnostics, Llc Stable formulations of humanized anti-tau antibody
GB201608323D0 (en) * 2016-05-12 2016-06-29 Ucb Biopharma Sprl Pharmaceutical compositions

Also Published As

Publication number Publication date
WO2019180261A1 (en) 2019-09-26
EP3768706A1 (en) 2021-01-27
TW202003036A (zh) 2020-01-16
US20210023216A1 (en) 2021-01-28
AU2019237252A1 (en) 2020-10-22
AR117407A1 (es) 2021-08-04
BR112020019065A2 (pt) 2020-12-29
JP2021519268A (ja) 2021-08-10
MX2020009935A (es) 2021-01-08
CN112004827A (zh) 2020-11-27
CA3094934A1 (en) 2019-09-26

Similar Documents

Publication Publication Date Title
AR117407A1 (es) Formulaciones acuosas estables de anticuerpos anti-tau
CU20190015A7 (es) Formulaciones de anticuerpos inhibidores de masp-2 altamente concentrados, de baja viscosidad y composiciones farmacéuticas que las comprenden
UY38080A (es) FORMULACIÓN FARMACÉUTICA DE pH BAJO
UY37952A (es) Formulaciones de un inhibidor de la quinasa trk macrocíclica
CY1123657T1 (el) Σταθερη φαρμακοτεχνικη μορφη anti-ifnar1
CO2018008754A2 (es) Composición farmacéutica que comprende constructos de anticuerpo biespecíficos
NZ743964A (en) Aqueous pharmaceutical formulation comprising anti-pd-1 antibody avelumab
AR108240A1 (es) Formulaciones que contienen anticuerpos
AR112271A1 (es) Composiciones que comprenden un inhibidor de arn polimerasa y ciclodextrina para el tratamiento de infecciones virales
CL2019000586A1 (es) Composiciones de toxinas clostridiales no proteicas.
BR112017008660A2 (pt) formulação de solução de proteína estável contendo alta concentração de um anticorpo anti-vegf
MX2019010282A (es) Formulacion de anticuerpos monoclonales.
EP4349327A3 (en) Emulsion formulations of multikinase inhibitors
CL2019002478A1 (es) Formulación de anticuerpo monoclonal anti-vrs.
AU2019339740A8 (en) CSF-1R antibody formulation
CO5720212A1 (es) Composicion de anticuerpo her2
MD3479819T2 (ro) Preparat farmaceutic lichid stabil
BR112017003419A2 (pt) formulação de anticorpo anti-il-4r-alfa estável
BR112022016456A2 (pt) Formulações de anticorpos anti-tslp humanos e métodos de uso dos mesmos
BR112022013292A2 (pt) Composição farmacêutica contendo anticorpo anti-btla e uso da mesma
CL2023000486A1 (es) Formulación farmacéutica que comprende un bite, anticuerpo biespecífico y metionina
MX2023014616A (es) Formulaciones de anticuerpos anti-pd1.
AR117607A1 (es) Formulaciones de anticuerpo líquidas de alta concentración
BR112022022620A2 (pt) Formulações de anticorpos anti-il-33
BR112023001471A2 (pt) Composição farmacêutica de anticorpo anti-pd-1 e uso da mesma

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20240513